Clinical trials · California
Lung cancer clinical trials in California
We’re tracking 303 recruiting lung cancer studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT07098338RecruitingPhase 2
New drug combos for advanced lung cancer
This trial tests new drug combinations for people with advanced or metastatic non-small cell lung cancer (NSCLC). Depending on your PD-L1 level and genetic profile, you may be placed in one of three groups to see if these combinations help shrink or control your tumor.
Santa Monica, CaliforniaAges 18 years+ - NCT06692738RecruitingPhase 3
Is a new immunotherapy better than Keytruda for squamous lung cancer?
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda), both combined with chemotherapy, as a first treatment for advanced squamous non-small cell lung cancer. It aims to see which combination works better.
Anaheim, CaliforniaAges 18 years+ - NCT06568939RecruitingPhase 2
Study of telisotuzumab vedotin for non-squamous lung cancer
This trial tests a drug called telisotuzumab vedotin (ABBV-399) given through a vein to people with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer) that has a high level of a protein called c-Met. The study aims to see how the drug affects the body and helps control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06236438RecruitingPhase 2/Phase 3
Livmoniplimab plus budigalimab and chemo for untreated lung cancer
This trial tests a new combination of two immune system drugs (livmoniplimab and budigalimab) plus standard chemotherapy compared to the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has not been treated yet. The goal is to see if the new combination works better at controlling the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT05257551Recruiting
Small cell lung cancer data study using tumor and blood samples
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
Los Alamitos, CaliforniaAges 18 years+ - NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Anaheim, CaliforniaAges 18 years+ - NCT04302025RecruitingPhase 2
Testing targeted and immunotherapy before lung cancer surgery
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
Duarte, CaliforniaAges 18 years+ - NCT07216105RecruitingPhase 1
New immune cell treatment for advanced solid tumors
This trial tests a new treatment using specially engineered immune cells (called FT836) for people with advanced solid tumors that have not responded to other treatments. It may be given alone or with chemotherapy and/or other antibody medicines. The study aims to see if this approach can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT05882058RecruitingPhase 2
Dose test of a DLL3 cancer drug for neuroendocrine tumors
This Phase 2 study tests how different doses of BI 764532 affect people with small cell lung cancer or certain other neuroendocrine cancers. It may help shrink tumors and improve symptoms after standard treatments have stopped working.
San Francisco, CaliforniaAges 18 years+ - NCT06758401RecruitingPhase 3
Study of combination treatment for advanced lung cancer with high PD-L1
This trial tests a new combination of two medicines (sigvotatug vedotin and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has high levels of a protein called PD-L1. The treatment is designed to help your immune system fight the cancer more effectively, and this study aims to see how well it works.
Fullerton, CaliforniaAges 18 years+ - NCT07144280RecruitingPhase 3
Study of a new drug vs docetaxel for advanced lung cancer
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
Berkeley, CaliforniaAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 19 years+ - NCT07513376RecruitingPhase 3
Adjuvant vaccine plus immunotherapy for high-risk early lung cancer
This trial tests whether giving a personalized cancer vaccine (Intismeran) with or without an immunotherapy drug (pembrolizumab) after lung cancer surgery can help prevent the cancer from coming back in patients with early-stage, high-risk non-small cell lung cancer.
Sacramento, CaliforniaAges 18 years+ - NCT07037758RecruitingPhase 1
Study of tarlatamab and AB248 for extensive stage small cell lung cancer
This trial tests a new combination of two drugs, tarlatamab and AB248, for people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Los Angeles, CaliforniaAges 18–90 - NCT06598306RecruitingPhase 1
Tarlatamab injection for advanced small cell lung cancer
This trial tests a new drug called tarlatamab, given as an injection under the skin (like a shot), for people with advanced small cell lung cancer that has worsened after chemotherapy. The goal is to see if this treatment can help shrink or slow down the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT05920356RecruitingPhase 3
Tested KRAS-targeted sotorasib plus chemo vs pembrolizumab plus chemo
This Phase 3 trial tests whether sotorasib plus standard chemotherapy works better than pembrolizumab (an immunotherapy) plus standard chemotherapy as first treatment for certain advanced lung cancers. It may help people whose tumors have a KRAS G12C mutation and that do not show PD-L1 on testing.
Santa Barbara, CaliforniaAges 18–100 - NCT07293247RecruitingPhase 2
Targeted radiation after lung cancer surgery
This trial tests if targeted radiation after surgery can help people with non-small cell lung cancer who still have cancer in their lymph nodes after chemotherapy. Participants will have had surgery and chemotherapy before starting radiation.
Los Angeles, CaliforniaAges 18 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
San Diego, CaliforniaAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT05642572RecruitingPhase 2
Test drug combinations for EGFR- and MET-changed lung cancer
This Phase 2 trial tests combinations of targeted medicines to treat advanced non-small cell lung cancer (NSCLC) that has changes in both EGFR and MET genes. It is for people whose cancer continued to grow even after treatment with osimertinib, the most recent therapy.
Auburn, CaliforniaAges 18 years+ - NCT07680790RecruitingPhase 3
New drug combination for advanced egfr lung cancer
This study tests a new drug (izalontamab brengitecan) combined with a standard targeted therapy (osimertinib) compared to standard treatments alone for advanced EGFR-mutant non-small cell lung cancer. It aims to see if the combination works better.
Beverly Hills, CaliforniaAges 18 years+ - NCT07491497RecruitingPhase 1/Phase 2
TRI-611 for ALK-positive lung cancer
This study tests an experimental pill for people with a specific type of lung cancer. The trial will see if the drug is safe and if it helps shrink tumors.
San Francisco, CaliforniaAges 18 years+ - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Duarte, CaliforniaAges 18 years+ - NCT03774758Recruiting
Blood tests to estimate lung cancer risk over 3 years
This study looks for blood “biomarkers” (measurable signs in blood) that may help predict who is at higher or lower risk related to lung cancer. You would have blood samples taken and then be followed with visits for up to 3 years.
San Francisco, CaliforniaAges 40 years+
Lung cancer trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting lung cancer studies listed above.
- UC San Diego Moores Cancer Center · 3 studies
- University of California, San Francisco · 3 studies
- Alta Bates Summit Medical Center-Herrick Campus · 2 studies
- Cancer and Blood Specialty Clinic · 2 studies
- Cedars-Sinai Medical Center · 2 studies
- Local Institution · 2 studies
- Providence Medical Foundation · 2 studies
- Providence St. Jude Medical Center · 2 studies
What taking part in a lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lung cancer trials in other states
Common questions
- Are there lung cancer clinical trials in California?
- Yes. We're currently tracking 303 recruiting lung cancer studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.